LEO Science & Tech Hub, a unit of Danish LEO Pharma, has collaborated with US-based skin sensors developer Epicore Biosystems to investigate a non-invasive, wearable sweat sensor.
The partners will explore the use of the sweat sensor in real-time measurement of prognostic biomarkers, monitoring patient response and aiding treatment decisions.
Initially, a proof-of-concept study will be conducted to determine baseline measurements and milestones in order to confirm the clinical relevance of the device for atopic dermatitis patients.
The study will be performed in alliance with engineers and dermatologists from Northwestern University’s Center for Bio-Integrated Electronics, and the Department of Dermatology at Feinberg School of Medicine in the US.
It is expected that the sweat sensor will facilitate real-time identification of skin hydration and disease-specific biomarker responses, thereby enabling personalised treatment regimens for patients.
LEO Science & Tech Hub vice-president Michael Sierra said: “A central goal of precision medicine is to predict early on if a given treatment will work for the individual patient. As atopic dermatitis (eczema) is a diverse skin disease, not all patients will benefit equally from a given treatment.
We believe that wearable technologies will have a major impact on the future of healthcare and LEO is fortunate for the opportunity to contribute our expertise in skin research and drug development to this project.”
The company’s chief data scientist Troels Marstrand noted that development of an at-home-patch test will allow patients to find early if they would benefit from a specific antibody therapy.
Epicore Biosystems co-founder and CEO Roozbeh Ghaffari said: “The possibilities for driving targeted therapies based on high throughput and low-cost analysis of biomarkers in sweat are limitless.
We’re excited about our partnership with LEO Science and Tech Hub, and see it leading to new classes of wearable metabolic sensors that enable remote tracking of skin disease biomarkers and help accelerate interventions once patients leave the hospital.”
Epicore Biosystems is a spinout company from professor John Rogers’ Laboratory at the Center for Bio-Integrated Electronics.